Logo image of BCTX

BRIACELL THERAPEUTICS CORP (BCTX) Stock Overview

USA - NASDAQ:BCTX - CA1079303071 - Common Stock

10.91 USD
+0.08 (+0.74%)
Last: 9/30/2025, 2:42:41 PM

BCTX Key Statistics, Chart & Performance

Key Statistics
52 Week High1905
52 Week Low7.28
Market Cap20.51M
Shares1.88M
Float1.79M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-83.2
PEN/A
Fwd PEN/A
Earnings (Next)10-27 2025-10-27/amc
IPO10-12 2006-10-12
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


BCTX short term performance overview.The bars show the price performance of BCTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 -40 -60 -80

BCTX long term performance overview.The bars show the price performance of BCTX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of BCTX is 10.91 USD. In the past month the price increased by 39.38%. In the past year, price decreased by -99.27%.

BRIACELL THERAPEUTICS CORP / BCTX Daily stock chart

BCTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.8 407.76B
AMGN AMGEN INC 13.02 152.86B
GILD GILEAD SCIENCES INC 14.62 140.41B
VRTX VERTEX PHARMACEUTICALS INC 23.37 101.49B
REGN REGENERON PHARMACEUTICALS 12.52 60.56B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 60.04B
ARGX ARGENX SE - ADR 79.56 45.13B
ONC BEONE MEDICINES LTD-ADR 5.89 40.09B
INSM INSMED INC N/A 30.62B
BNTX BIONTECH SE-ADR N/A 23.65B
NTRA NATERA INC N/A 22.22B
BIIB BIOGEN INC 8.77 20.59B

About BCTX

Company Profile

BCTX logo image Briacell Therapeutics Corp is a CA-based company operating in Biotechnology industry. The company is headquartered in West Vancouver, British Columbia and currently employs 17 full-time employees. The company went IPO on 2006-10-12. BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The firm is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. The company is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

Company Info

BRIACELL THERAPEUTICS CORP

Suite 300 - Bellevue Centre, 235 -15th Street

West Vancouver BRITISH COLUMBIA V7T 2X1 CA

CEO: William V. Williams

Employees: 17

BCTX Company Website

BCTX Investor Relations

Phone: 16049211810

BRIACELL THERAPEUTICS CORP / BCTX FAQ

What is the stock price of BRIACELL THERAPEUTICS CORP today?

The current stock price of BCTX is 10.91 USD. The price increased by 0.74% in the last trading session.


What is the ticker symbol for BRIACELL THERAPEUTICS CORP stock?

The exchange symbol of BRIACELL THERAPEUTICS CORP is BCTX and it is listed on the Nasdaq exchange.


On which exchange is BCTX stock listed?

BCTX stock is listed on the Nasdaq exchange.


What is BRIACELL THERAPEUTICS CORP worth?

BRIACELL THERAPEUTICS CORP (BCTX) has a market capitalization of 20.51M USD. This makes BCTX a Nano Cap stock.


How many employees does BRIACELL THERAPEUTICS CORP have?

BRIACELL THERAPEUTICS CORP (BCTX) currently has 17 employees.


What are the support and resistance levels for BRIACELL THERAPEUTICS CORP (BCTX) stock?

BRIACELL THERAPEUTICS CORP (BCTX) has a resistance level at 11.05. Check the full technical report for a detailed analysis of BCTX support and resistance levels.


Should I buy BRIACELL THERAPEUTICS CORP (BCTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BRIACELL THERAPEUTICS CORP (BCTX) stock pay dividends?

BCTX does not pay a dividend.


When does BRIACELL THERAPEUTICS CORP (BCTX) report earnings?

BRIACELL THERAPEUTICS CORP (BCTX) will report earnings on 2025-10-27, after the market close.


What is the Price/Earnings (PE) ratio of BRIACELL THERAPEUTICS CORP (BCTX)?

BRIACELL THERAPEUTICS CORP (BCTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-83.2).


BCTX Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to BCTX. When comparing the yearly performance of all stocks, BCTX is a bad performer in the overall market: 99.98% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BCTX Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to BCTX. BCTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BCTX Financial Highlights

Over the last trailing twelve months BCTX reported a non-GAAP Earnings per Share(EPS) of -83.2. The EPS decreased by -994.62% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -123.71%
ROE -321.51%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-199.39%
Sales Q2Q%N/A
EPS 1Y (TTM)-994.62%
Revenue 1Y (TTM)N/A

BCTX Forecast & Estimates


Analysts
Analysts80
Price TargetN/A
EPS Next Y-431.62%
Revenue Next YearN/A

BCTX Ownership

Ownership
Inst Owners9.66%
Ins Owners3.94%
Short Float %N/A
Short Ratio0.03